Starpharma Holdings Limited · ASX:SPL
Starpharma — Investor Presentation (June 2007)
38 slides from Starpharma's investor presentation, June 2007

Slide 1: Starpharma Holdings Limited
Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY June 2007 Dr Jackie Fairley CEO

Slide 2: Forward-looking statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set

Slide 3: Company Overview
Company Overview World leader in developing dendrimer products Starpharma Holdings Limited (15/6/07) for pharmaceutical and life-sciences ASX Code SPL Level 1 ADR (OTCQX) SPHRY Lead product VivaGel™ is being developed (with Share Price SPL AUD 42.5c 12 Month High/Low AUD 64c / 35c >$20M NIH supp

Slide 4: Investment Summary
Investment Summary Starpharma has a leading topical microbicide (VivaGel™) in development for prevention of sexually transmitted infections (STIs) HIV and genital herpes Topical microbicides have strong consumer demand and funding support – By age 25 half of all sexually active people in the US

Slide 5: Company Structure
Company Structure 8.6% Starpharma Holdings Limited ASX:SPL USOTC:SPHRY 100% 100% Dendritic Nanotechnologies Starpharma Pty Ltd Inc. (DNT) 36 employees based in Melbourne, Wholly owned subsidiary based in Australia Michigan, USA (16 employees) Leading developer of dendrimers as Leading develo

Slide 6: Shareholding and ADR (SPHRY) Uptake
Shareholding and OTCQX:SPHRY Major shareholders include: ADR (SPHRY) Uptake The Dow Chemical Company (NASDQ:DOW) OTCQX : SPHRY Acorn Capital American Depositary Receipts (ADRs) on issue Biotech Capital 1 ADR = 10 SPL shares 2,000,000 1,800,000 Queensland Investment Corporation 1,600,000 1,

Slide 7: Technology Overview
Technology Overview Starpharma’s existing Unique Characteristics of Dendrimers: commercial agreements for dendrimers Precisely defined, synthetic macromolecules (1-10nm) Precisely defined surface topology Stratus CS® : Cardiac marker Can be designed to optimize potency, pharmacokinetics and di

Slide 8: Technology Overview (continued)
Technology Overview (continued) Commercial Advantages of Dendrimers: O O Key enabling nanoscale technology O O O Highly versatile technology: O O O Therapeutic Protein O O O O N N – application as drugs (VivaGel), in drug delivery, RNAi N N O N O O O N N delivery, diagnostic & materials applicat

Slide 9: Product Pipeline
Og starpharma Product Pipeline

Slide 10: Starpharma's Pipeline: Balanced for Risk
Starpharma’s Pipeline: Balanced for Risk Pharmaceutical & Medical Products Proof of Concept Lead Clinical Trials Sales VivaGel™ * HSV-2 prevention * HIV prevention * condoms coating & other line extensions ADME Engineering™ * Therapeutic protein PK optimisation Drug Delivery - Small Molecules * Canc

Slide 11: VivaGel - Lead Product for Prevention of STIs
VivaGelTM - Lead Product for Prevention of Sexually Transmitted Infections STIs

Slide 12: VivaGel – Lead Product for Prevention of STIs
VivaGelTM – Lead Product for Prevention of Sexually Transmitted Infections (STIs) VivaGel™ is a topical vaginal microbicide being HIV developed to prevent STIs in women Major health burden in both Currently being developed under two INDs for the developed and developing countries prevention of

Slide 13: Commercial Opportunity for Microbicides
Commercial Opportunity for Microbicides Large, addressable markets Estimated Market for ¾ HIV primarily in developing countries microbicides in Developed Countries ¾ HSV-2 in both developing and developed countries Market Average Frequency Penetration of Use Per Annum Increasing market support f

Slide 14: VivaGel – Product Features and Performance
VivaGel™ – Product Features and Performance VivaGel™ Offers Market research indicates significant (international) user and payor demand for Several Key microbicide gels Advantages VivaGel™ will be “first in class” for Herpes Compelling HSV-2 &HIV efficacy and potent contraceptive activity in a

Slide 15: VivaGel - Clinical Trial Status
VivaGel™ - Clinical Trial Status Study No. Site(s) IND Status Participants Application Safety, tolerability and 37 Adelaide, Prevention of Complete pharmacokinetic study of Australia HIV escalating doses of VivaGel in healthy women when administered vaginally, once daily for 7 days Safety and accept

Slide 16: VivaGel - Development stage and plan
VivaGel™ - Development stage and plan PRODUCT TYPE Therapeutic In vitro In vivo In vivo Market Phase 1 Phase 2 Phase 3 Agent efficacy efficacy safety entry Preventative Expanded Population In vitro In vivo In vivo Market “Drug” Phase 1 Safety Based entry efficacy efficacy safety (VivaGel™) Studies e

Slide 17: VivaGel – Development and Commercial Strategy
VivaGelTM – Development and Commercial Strategy One of the most advanced 2nd generation microbicides for HIV First in class for HSV-2 Significant non-dilutive NIH support; strong ongoing support for microbicides Broad application; chronic-use product VivaGel™ Partnering/commercial strategi

Slide 18: Portfolio: Overview of Opportunities
Portfolio: Overview of Opportunities Multiple Near-Term Future High-Value Commercial Commercial Opportunities Opportunities Pharmaceutical Industrial Products Life-science Applications Applications siRNA, DNA transfection VivaGel™ Industrial Reagents Chemicals Medical Protein Diagnostics PK Modifica

Slide 19: Portfolio: siRNA Delivery – PrioFect
Portfolio: siRNA Delivery – PrioFect™ Concept: Overcome the principle obstacle to the development of RNAi-based drugs … delivery Commercial opportunities for PrioFect™: “RNAi-based therapies have so far failed to take off because of the difficulty of 1. Research reagent market($200 million) getting

Slide 20: Portfolio: siRNA Delivery – PrioFect
Portfolio: siRNA Delivery – PrioFect™ Concept: Overcome the principle obstacle to the development of RNAi-based drugs … delivery Technology Inhibiting Protein Expression Significance Potential for Cell specific targeting 100 Enhanced residence time Protein Expression Protection from nucleases

Slide 21: Portfolio: Drug Optimization or Therapeutic Protein PK modification
Portfolio: Drug Optimization or Therapeutic Protein PK (pharmacokinetic) modification Concept: increase half life of drugs by attaching to dendrimer Technology Extending Drug Half Life Significance Potential for less frequent dosing Payload Drug 80 Reduced cost of therapy Circulatory Half-life (

Slide 22: Portfolio: Drug Delivery
Portfolio: Drug Delivery Concept: Attach drugs to dendrimers to control and modify distribution Technology Dendrimers can be Targeted Significance Optional Potential for Targeting Payload Improved efficacy of drugs Element Drug Reduced off-target effects Product lifecycle management Improved

Slide 23: Portfolio: Other Early Commercial Opportunities
Portfolio: Other Early Commercial Opportunities* Sector Discussions with… Application Research Reagents Major Reagent manufacturers Enhanced fluorescent dye performance Major Reagent manufacturers Other Laboratory reagents Oil "Top 5" US Oil Company Lubricant additives Plastics Large Automotive Comp

Slide 24: Partnerships and Collaborators
Partnerships and Collaborators Industry Collaborators Research/ University Collaborators NICHD NIAID 24

Slide 25: Key Management
Key Management Over 15 years international business development and general management Dr Jackie Fairley, CEO experience in pharmaceuticals and biotechnology Former senior roles with CSL and Faulding (Mayne Pharma) Dr Paul Barrett, VP Business Significant experience in marketing and business d

Slide 26: Key Investment Highlights
Key Investment Highlights Compelling competitive advantages VivaGel™: A Unique Clinical candidate with Significant support from NIH (>US$20M) Lead Product First in class for genital herpes HIV and genital herpes at epidemic proportions Significant Commercial (Genital herpes: US 22% adults &

Slide 27: Starpharma Holdings Limited
Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY Dr Jackie Fairley, CEO +613 85322704 SPL US$M Market Capitalisation ~60 Further information: NIH Support >26 www.starpharma.com Cash on Hand (Mar 07) 10.7 info@starpharma.com

Slide 28: Supplementary Information
Og starpharma Upplementary | ntormation

Slide 29: Starpharma: 06/07 Highlights
Starpharma: 06/07 Highlights Acquisition of DNT SPL acquires US company DNT Dow becomes SPL’s largest holder Integration of SPL and DNT complete Richard Hazelton appointment Retired Dow Corning Chairman/CEO appointed to SPL Board VivaGel™ clinical trial progress Expanded safety trial in men complete

Slide 30: Portfolio: Fluorescent Reagents
Portfolio: Fluorescent Reagents Concept: Attach fluorescent dyes on dendrimers to enhance biomolecular signal Technology Enhanced, Stabilized Signal Significance >4X Longer Lasting! Potential for Fluorescence Microscopy Linker Dye Microarrays Antibody based kits (ELISA) 10X In vitro Diagnost

Slide 31: Portfolio: Cosmetic Ingredient Solubilizer
Portfolio: Cosmetic Ingredient Solubilizer Concept: Use dendrimers to enhance solubility, stability, processing Technology Low % = Improve Solubility Significance Poorly Potential for Soluble Increasing ingredient loading Ingredient Stabilize ingredient Improved processing Allowing new ingre

Slide 32: VivaGel: Animal Efficacy results – SHIV/HIV Protection
VivaGel™: Animal Efficacy results SHIV/HIV Protection Advantage: VivaGel™ is NOT a surfactant Surfactants damage epithelial cells INCREASING the chance of HIV transmission. VivaGel is NOT a surfactant and has been found not to damage epithelial cells in human trials. This is not true of all microbic

Slide 33: VivaGel: Animal Efficacy results (continued) – HSV Protection
VivaGel™: Animal Efficacy results (continued) HSV Protection VivaGel™: animals protected from HSV-2 100% Approximately 45 million Americans (26% 90% Approximately 45 million Americans (26% ofofwomen women and 18%ofofmen) and 18% men)are areinfected infected 80% with HSV-2, the causative agent of gen

Slide 34: VivaGel: Potent Contraceptive Activity in Rabbits
VivaGel™ : Potent Contraceptive Activity in Rabbits Recent study has shown that SPL7013, the active ingredient in its VivaGel™, exhibits a potent contraceptive effect in rabbits Independent study undertaken at Johns Hopkins University under an NIH grant Fertility was reduced by more than 75% b

Slide 35: VivaGel: Significant Advantages Over Competitors
VivaGel™ : Significant Advantages Over Competitors Competitor Category Key Disadvantages VivaGel™ Advantages HSV-2 VivaGel™ is the only microbicide being developed to prevent genital herpes Surfacants/Detergents Ulceration possible No surfactant properties Potential increased risk of Non-irr

Slide 36: Pipeline: Commercialisation Strategy
Pipeline: Commercialisation Strategy Product/ Projected / actual Category Approach Stage Application Income type Milestones VivaGel™ Late stage partnering deal to retain value Clinical Royalties “In house” Milestones Other Drugs, Pharmaceutical Preclinical out-license Pre-clincial e.g cancer therape

Slide 37: Pipeline: Drug Delivery & PK Modification of Protein Therapeutics
Pipeline: Drug Delivery & PK Modification of Protein Therapeutics Starpharma’s dendrimers can be designed to optimize the Pharmacokinetics (PK) of: Small molecule drugs O O Therapeutic proteins O O O Peptides O O O Therapeutic Protein O O Plasma residence time increases with dendrimer size, but: O O

Slide 38: RNAi therapeutics
RNAi therapeutics Company Clinical Development Pre-clinical development Acuity Ph II AMD & DME anti-inflammatories & anti-infectives Alnylam Ph 1 2006 (RSV) pandemic flu, spinal cord injury, Parkinson’s, cystic fibrosis, hypercholesterolemia, neuropathic pain Sirna Ph II AMD (w/ Allergan) Asthma, RS
Source: Internet Archive copy of starpharma.com
More decks from Starpharma Holdings Limited
Shareholder Meeting (November 2026)31 slides · Nov 6, 2026
Investor Presentation (October 2026)17 slides · Oct 21, 2026
Investor Presentation (July 2026)45 slides · Jul 15, 2026
Shareholder Meeting (November 2025)35 slides · Nov 14, 2025
Australian Microcap Investment Conference 202527 slides · Oct 21, 2025
Merger or Acquisition (September 2025)8 slides · Sep 22, 2025